AR040407A1 - Compuestos heterociclicos inhibidores de la funcion del canal de potasio - Google Patents

Compuestos heterociclicos inhibidores de la funcion del canal de potasio

Info

Publication number
AR040407A1
AR040407A1 AR20030101347A ARP030101347A AR040407A1 AR 040407 A1 AR040407 A1 AR 040407A1 AR 20030101347 A AR20030101347 A AR 20030101347A AR P030101347 A ARP030101347 A AR P030101347A AR 040407 A1 AR040407 A1 AR 040407A1
Authority
AR
Argentina
Prior art keywords
alkyl
independently
aryl
groups
heteroaryl
Prior art date
Application number
AR20030101347A
Other languages
English (en)
Inventor
Adam Lloyd
Yoon T Jeon
Heather Finlay
Lin Yan
Serge Beaudoin
Michael F Gross
Original Assignee
Bristol Myers Squibb Co
Icagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Icagen Inc filed Critical Bristol Myers Squibb Co
Publication of AR040407A1 publication Critical patent/AR040407A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Inhibidores de la función del canal de potasio (especialmente inhibidores de la subfamilia Kv1 de los canales de K+ que se abren con voltaje, especialmente los inhibidores Kv1.5 que se han ligado a la corriente Ikur- del rectificador K+ retrasada de activación ultrarrápida), métodos de uso de tales compuestos en la prevención y tratamiento de la arritmia y condiciones asociadas con Ikur-, y a composiciones farmacéuticas que contienen tales compuestos. Reivindicación 1: Un compuesto de la fórmula (1) enantiómeros, diastereómeros, sales y solvatos de los mismos donde m y p son independientemente 0, 1, 2 o 3 con la condición de que la suma de m y p es de al menos 2; Q es NR1, O, S, S(O) o S(O)2; R1 es un radical del grupo de fórmulas (2), -C(=NR8b)R8c, -SO2R8c, -OC(O)CCl3, -C(=S)R8c, arilo opcionalmente substituido, heteroarilo opcionalmente substituido, heterociclo opcionalmente substituido, perfluoroalquilo, ciano, hidroxi, alcoxi opcionalmente substituido, ariloxi opcionalmente substituido, heteroariloxi opcionalmente substituido, alquilo opcionalmente substituido, cicloalquilo opcionalmente substituido, alquenilo opcionalmente substituido, o alquinilo opcionalmente substituido; R2 es heteroarilo, (heteroaril)alquilo, arilo, (aril)alquilo, heterociclo, (heterociclo)alquilo, alquilo o cicloalquilo, cualquiera de los cuales puede estar opcionalmente substituido independientemente con uno o más grupos T1, T2 o T3; J es un enlace, alquileno C1-4 opcionalmente substituido independientemente con uno o más grupos T1a,T2a o T3a, o alquenileno C1-4 opcionalmente substituido independientemente con uno o más grupos T1a, T2a o T3a ; R3 es un radical del grupo de fórmulas (3); R4 es H, alquilo, haloalquilo, alquenilo, alquinilo, cicloalquilo, heterociclo, arilo, (aril)alquilo o heteroarilo cualquiera de los cuales puede estar opcionalmente substituido independientemente con uno o más grupos T1b, T2b o T3b ; R5 es (a) -NR6aR7a, ciano o (b) heteroarilo, (heteroaril)alquilo, arilo, (aril)alquilo, alquilo, cicloalquilo, (cicloalquil)alquilo, heterociclo, (heterociclo)alquilo, o alquilo cualquiera de los cuales puede estar opcionalmente substituido independientemente con uno o más grupos T1c, T2c o T3c; R6, R6a, R7, R7a, R8, R8a, R8a1, R8a2, y R8a3 son independientemente H, alquilo, hidroxi, alcoxi, ariloxi, heterociclooxi, heteroariloxi, (hidroxi)alquilo, (alcoxi)alquilo, (ariloxi)alquilo, (heterociclooxi)alquilo, (heteroariloxi)alquilo, (ciano)alquilo, (alquenil)alquilo, (alquinil)alquilo, cicloalquilo, (cicloalquil)alquilo, arilo, (aril)alquilo, heteroarilo, (heteroaril)alquilo, heterociclo, (heterociclo)alquilo, -C(O)R9, -CO2R9, -C(O)-NR9R10, o -NR9R10 cualquiera de los cuales puede estar opcionalmente substituido independientemente con uno o más grupos T1d, T2d o T3d; o R6 y R7, o R6a y R7a junto con el átomo de nitrógeno al cual se enlazan, pueden combinarse para formar un anillo heterociclo de 4 hasta 8 miembros opcionalmente substituido independientemente con uno o más grupos T1d, T2d o T3d; o uno de R6 o R7, puede combinarse con uno de R8, R8a o R9 pueden combinarse para formar un anillo de 5 hasta 8 miembros saturado o no saturado opcionalmente substituido independientemente con uno o más grupos T1d, T2d o T3d; o uno de R6a o R7a, pueden combinarse con R8a1 para formar un anillo de 5 hasta 8 miembros saturado o no saturado opcionalmente substituido independientemente con uno o más grupos T1d, T2d o T3d; R8b es independientemente H, alquilo, arilo, ciano, nitro, acilo o -SO2(alquilo) donde los grupos alquilo y arilo pueden estar opcionalmente substituido independientemente con uno o más grupos T1d, T2d o T3d; R8c es H, alquilo, cicloalquilo, alquenilo, alquinilo, arilo, arilalquilo, heterociclo, heteroarilo, alcoxi o ariloxi cualquiera de los cuales puede estar opcionalmente substituido independientemente con uno o más grupos T1d, T2d o T3d; R8d es R4, COR4, CO2R4, SO2R4, CONR6R7, o SO2NR6R7; R9 y R10 son independientemente H, alquilo, hidroxi, alcoxi, ariloxi, heterociclooxi, heteroariloxi, (hidroxi) alquilo, (alcoxi)alquilo, (ariloxi)alquilo, (heterocilooxi)alquilo, (heteroariloxi)alquilo, cicloalquilo, (cicloalquil)alquilo, arilo, (aril)alquilo, heteroarilo, (heteroaril)alquilo, heterociclo, o (heterociclo)alquilo cualquiera de los cuales puede estar opcionalmente substituido independientemente con uno o más grupos T1f, T2f o T3f o R9 y R10 juntos con el átomo de nitrógeno al cual se enlazan pueden combinarse para formar un anillo saturado o no saturado que puede estar opcionalmente substituido independientemente con uno o más grupos T1f, T2f o T3f; W es =NR8a1, =N-CO2R8a1, =N-COR8a1, =N-CN, =N-SO2R8a1, o =CHNO2; X1 es O, S, NR8a2 o CH2; Z, Z1 y Z2 son independientemente =O, =S, =NR8a3 o =N-CN; Rx es uno o más substituyentes opcionales, enlazados a cualquier átomo de carbono en el anillo disponible, independientemente seleccionado de T1g, T2g o T3g; T1-1g, T2-2g, y T3-3g son cada uno independientemente (1) hidrogeno o T6, donde T6 es (i) alquilo, (hidroxi)alquilo, (alcoxi)alquilo, alquenilo, alquinilo, cicloalquilo, (cicloalquil)alquilo, cicloalquenilo, (cicloalquenil)alquilo, arilo, (aril)alquilo, heterociclo, (heterociclo)alquilo, heteroarilo, o (heteroaril)alquilo; (ii) un grupo (i) que por si mismo está substituido por uno o más de los mismos o diferentes grupos (i); o (iii) un grupo (i) o (ii) que está independientemente substituido por uno o más (preferiblemente 1 a 3) de los siguientes grupos (2) hasta (13) de la definición de T1-1g, T2-2g y T3-3g, (2) -OH o -OT6, (3) -SH o -ST6, (4) -C(O)tH, -C(O)tT6, o -O-C(O)T, en donde t es 1 o 2; (5) -SO3H, -S(O)tT6, o S(O)tN(T9)T6, (6) halo, (7) ciano, (8) nitro, (9) -T4-NT7T8, (10) -T4-N(T9)-T5-NT7T8, (11) -T4-N(T10)-T5-T6, (12) -T4-N(T10)-T5-H, (13) oxo; T4 y T5 son cada uno independientemente (1) un enlace sencillo, (2) -T11S(O)t-T12 (3) -T11-C(O)-T12-, (4) -T11-C(S)-T12, (5) -T11-O-T12, (6) -T11-S-T12-, (7) -T11-O-C(O)-T12-, (8) -T11-C (O)-O-T12-, (9) -T11-C(=NT9a)-T12-, o (10) -T11-C(O)-C (O)-T12-; T7, T8, T9, T9a y T10 (1) son cada uno independientemente hidrogeno o un grupo proporcionado en la definición de T6, o (2) T7 y T8 pueden juntos ser alquileno o alquenileno, completando un anillo saturado o no saturado de 3 hasta 8 miembros juntos con los átomos a los cuales se enlazan, cuyo anillo está substituido o no substituido con uno o más grupos enlistados en la descripción de T1-1g, T2-2g y T3-3g; o (3) T7 o T8, junto con T9, puede ser alquileno o alquenileno completando un anillo saturado o no saturado de 3 hasta 8 miembros juntos con los átomos de nitrógeno a los cuales se enlazan, cuyo anillo está substituido o no substituido con uno o más grupos enlistados en la descripción de T1-1g, T2-2g y T3-3g; o (4) T7 y T8 o T9 y T10 junto con el átomo de nitrógeno al cual se enlazan, pueden combinarse para formar un grupo -N=CT13T14 donde T13 y T14 son cada uno independientemente H o un grupo proporcionado en la definición de T6; y T11 y T12 son cada uno independientemente (1) un enlace sencillo, (2) alquileno, (3) alquenileno, o (4) alquinileno; con la condición de que el compuesto es diferente a (i) un compuesto de fórmula (4) en donde R1i es H, alquilo, aralquilo, -C(O)alquilo, -C(O)arilo, -C(O)aralquilo, -C(O)alquileno -CO2alquilo, -CO2alquilo, -CO2alquenilo, -CO2aralquilo, o - SO2alquilo ; y R8i es H, o alquilo; (ii) un compuesto de fórmula iia, iib o iic en donde es 0, 1 o 2; y R1iib es H o -C(O)2alquilo; (c) en donde R1iic es H o alquilo; y R8iic es H o alquilo; (iii) un compuesto de fórmula iii en donde R1iii es -alquiIeno-C(O)-Ar en donde Ar es fenilo, alquilfenilo, xililo, halofenilo, metoxifenilo o tienilo; y R2iii es tienilo, fenilo, halofenilo, metoxifenilo, alquilfenilo, xililo, o trifluorometilfenilo; (iv) un compuesto de fórmula iv en donde R1iv es (5) ,donde T1h es alquilo, arilo, heteroarilo, (aril)alquilo, (heteroaril)alquilo, (cicloalquil)alquilo, -alquileno-M-alquilo, -alquileno-M-alquileno-arilo, -alquileno-M-alquileno-heteroarilo, -alquileno-M-alquileno-cicloalquilo en donde los grupos alquilo y alquileno pueden estar opcionalmente substituidos con 1 hasta 5 halo, -S(O)qH, -S(O)qalquilo, o 1 a 3 hidroxi, alcoxi, carboxilo o -C(O)Oalquilo, y en donde los grupos arilo y heteroarilo pueden estar opcionalmente substituidos con fenilo, fenoxi, (aril)alcoxi, (heteroaril)alcoxi, halofenilo, 1 hasta 3 halo o alquilo,1 hasta 3 metoxi, alcoxi, o cicloalcoxi, 1 hasta 3 trifluorometilo o trifluorometoxi, 1 hasta 2 metilendioxi, S(O)qR5b, nitro, -NR5bR5b, -NR5bC(O)R5b, -C(O)OR5b, -C(O)NR5bR5b, -SO2NR5bR5b, -NR5bSO2arilo, -NR5bSO2heteroarilo, o -NR5bSO2R5b ; M es O, SOq, NR5bC(O), C(O)NR5b, OC(O), C(O)O, -CR5b=CR5b-, o -C:::C-; T2h es H, alquilo, o cicloalquilo; o T1h y T2h se combinan para formar un anillo de 3 hasta 8 miembros que incluye opcionalmente heteroátomos; T3h es -LC(O)ANR6dR7d; L es NR5c, O o CH2, R5c es H, alquilo o R5c combinado con T2h forman un anillo de 3 hasta 8 miembros; R6d y R7d son independientemente H, alquilo, o alquilo substituido en donde los substituyentes se seleccionan de fenilo, fenoxi, 2-furilo, -C(O)Oalquilo, -S(O)qalquilo, 1 a 5 halo, 1 a 3 hidroxi, 1 a 3 -OC(O)alquilo, o 1 a 3 alcoxi, o R6d y R7d pueden combinarse para formar un anillo no saturado que contiene opcionalmente heteroátomos adicionales; A es un enlace o (6) en donde r y s son independientemente 0-3; Q1 es un enlace, NR5b o O; R15 y R15a son independientemente H, alquilo, trifluorometilo, fenilo o alquilo opcionalmente substituido en donde los substituyentes se seleccionan de imidazolilo, fenilo, indolilo, p-hidroxifenilo, OR, S(O)qR5b, C(O)OR5b, cicloalquilo, NR5bR5b, C(O)NR5bR5b, o R15 y R15a pueden independientemente unirse a uno o ambos de R6d y R7d para formar puentes alquileno entre el nitrógeno terminal y la porción alquilo del grupo R15 y R15a, o R15 y R15a pueden combinarse para formar un anillo de 3 hasta 7 miembros; R2iv es alquilo, cicloalquilo, arilo
AR20030101347A 2002-04-19 2003-04-16 Compuestos heterociclicos inhibidores de la funcion del canal de potasio AR040407A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37427902P 2002-04-19 2002-04-19

Publications (1)

Publication Number Publication Date
AR040407A1 true AR040407A1 (es) 2005-04-06

Family

ID=29251169

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20030101347A AR040407A1 (es) 2002-04-19 2003-04-16 Compuestos heterociclicos inhibidores de la funcion del canal de potasio

Country Status (13)

Country Link
US (3) US7005436B2 (es)
EP (3) EP2228065B1 (es)
JP (2) JP4729259B2 (es)
AR (1) AR040407A1 (es)
AT (1) ATE557005T1 (es)
AU (1) AU2003223651A1 (es)
ES (1) ES2388034T3 (es)
IS (1) IS7502A (es)
NO (1) NO20044351L (es)
PE (1) PE20040685A1 (es)
PL (1) PL373313A1 (es)
TW (1) TW200403058A (es)
WO (1) WO2003088908A2 (es)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
US7435824B2 (en) * 2002-04-19 2008-10-14 Bristol-Myers Squibb Company Prodrugs of potassium channel inhibitors
RU2005118407A (ru) * 2002-12-13 2006-03-10 СмитКлайн Бичем Корпорейшн (US) Производные пиперидина в качестве антагонистов ccr5
FR2854158B1 (fr) 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
GB0310724D0 (en) * 2003-05-09 2003-06-11 Glaxo Group Ltd Chemical compounds
TWI290140B (en) * 2003-08-25 2007-11-21 Schering Corp 2-Substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for thr treatment of obesity and related disorders
AR045496A1 (es) 2003-08-29 2005-11-02 Schering Corp Analolgos de benzimidazolpiperidinas 2- substiyuidas como antagonistas de los receptores de la hormona que concentra melanina selectivos para el tratamiento de la obesidad y trastornos relacionados
ES2298832T3 (es) * 2003-10-24 2008-05-16 Glaxo Group Limited Compuestos heterociclicos.
WO2005046601A2 (en) * 2003-11-12 2005-05-26 Merck & Co., Inc. 4-phenyl piperdine sulfonyl glycine transporter inhibitors
US8759335B2 (en) * 2004-01-30 2014-06-24 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
KR100886002B1 (ko) * 2004-01-30 2009-03-03 유로-셀띠끄 소시에떼 아노님 4-테트라졸릴-4-페닐피페리딘 화합물의 제조방법
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
CA2560256C (en) * 2004-03-24 2013-02-19 Merck & Co., Inc. Heteroaryl piperidine glycine transporter inhibitors
US20080096922A1 (en) * 2004-04-06 2008-04-24 Dainippon Sumitomo Pharma Co., Ltd. Novel Sulfonamide derivative
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
CN1696115B (zh) * 2004-05-11 2010-06-09 中国科学院上海药物研究所 合成砌块4-取代基-4-氨基-哌啶衍生物、其制备方法和用途
GB0412865D0 (en) 2004-06-09 2004-07-14 Glaxo Group Ltd Chemical compounds
FR2872813B1 (fr) 2004-07-09 2007-01-19 Sanofi Synthelabo Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique
US7776886B2 (en) 2004-09-30 2010-08-17 Merck Sharp & Dohme Corp. Cyclopropyl piperidine glycine transporter inhibitors
FR2876692B1 (fr) 2004-10-19 2007-02-23 Sanofi Aventis Sa Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US20060167044A1 (en) * 2004-12-20 2006-07-27 Arnaiz Damian O Piperidine derivatives and their use as anti-inflammatory agents
AU2005317846B2 (en) * 2004-12-21 2011-12-08 Merck Sharp & Dohme Limited Piperidine and azetidine derivatives as GlyT1 inhibitors
WO2006106423A2 (en) * 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
EP1939189A4 (en) 2005-08-26 2013-03-13 Shionogi & Co DERIVATIVE HAVING AGONIST ACTIVITY AGAINST PPAR
US7915410B2 (en) 2005-09-09 2011-03-29 Bristol-Myers Squibb Company Acyclic IKur inhibitors
EP2270014A1 (en) 2005-09-22 2011-01-05 Incyte Corporation Azepine inhibitors of janus kinases
WO2007053400A2 (en) * 2005-10-28 2007-05-10 Merck & Co., Inc. Piperidine glycine transporter inhibitors
EP2404919B1 (en) 2005-11-08 2013-08-21 Vertex Pharmaceuticals Incorporated Heterocyclic compound useful as a modulator of ATP-binding cassette transporters.
MY159449A (en) * 2005-12-13 2017-01-13 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
JP5165586B2 (ja) * 2005-12-28 2013-03-21 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症の処置のためのＡＴＰ結合カセットトランスポーターのモジュレーターとしての、１−（ベンゾ［ｄ］［１，３］ジオキソール−５−イル）−Ｎ−（フェニル）シクロプロパン−カルボキサミド誘導体および関連化合物
FR2895989B1 (fr) 2006-01-06 2010-04-30 Sanofi Aventis Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique
AR059517A1 (es) 2006-02-17 2008-04-09 Wyeth Corp N- sulfonilacion selectiva de alcoholes sustituidos con 2- aminotrifluoralquilo
BRPI0707741A2 (pt) 2006-02-17 2011-05-10 Wyeth Corp mÉtodos para preparar um amino Álcool, ou sal do mesmo, e um Álcool substituÍdo por sulfonamida
EP2043655A2 (en) 2006-04-25 2009-04-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
DE102006049527A1 (de) * 2006-10-20 2008-04-24 Sanofi-Aventis Deutschland Gmbh Inhibitoren des TASK-1 und TASK-3 Ionenkanals
AU2007275301A1 (en) 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1
WO2009010810A2 (en) * 2006-08-07 2009-01-22 Wockhardt Limited Cardiovascular combinations comprising ace and hmg-co-a inhibitors
EP2059506A1 (en) * 2006-08-30 2009-05-20 Neurosearch A/S Novel piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US8043829B2 (en) * 2006-10-25 2011-10-25 Amgen Inc. DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression
ES2401129T3 (es) 2006-12-19 2013-04-17 F. Hoffmann-La Roche Ag Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
CA2673038C (en) 2006-12-22 2015-12-15 Incyte Corporation Substituted tricyclic heteroaryl compounds as janus kinase inhibitors
EP2114415A4 (en) * 2007-02-23 2012-10-17 Univ Louisville Res Found METHOD AND COMPOUNDS FOR THE TARGETED RELEASE OF ACTIVE SUBSTANCES IN BONES FOR INTERACTION THEREOF
US20080221070A1 (en) * 2007-03-06 2008-09-11 Pierce William M Methods and compounds for the targeted delivery of agents to bone for interaction therewith
US8969386B2 (en) 2007-05-09 2015-03-03 Vertex Pharmaceuticals Incorporated Modulators of CFTR
AU2008262490B2 (en) * 2007-05-22 2011-11-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
CL2008001709A1 (es) * 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
TR201903488T4 (tr) 2007-06-13 2019-04-22 Incyte Holdings Corp Janus kinaz inhibitörü (r)-3-(4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-siklopentilpropannitril tuzlarının kullanımı.
PL2201012T3 (pl) 2007-10-11 2014-11-28 Astrazeneca Ab Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
US20100036130A1 (en) * 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
PL2225230T3 (pl) 2007-12-07 2017-08-31 Vertex Pharmaceuticals Incorporated Stałe postacie kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego
MX364936B (es) 2007-12-07 2019-05-15 Vertex Pharma Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos.
US8569282B2 (en) * 2007-12-11 2013-10-29 Cytopathfinder, Inc. Carboxamide compounds and their use
ES2647531T3 (es) 2008-02-28 2017-12-22 Vertex Pharmaceuticals Incorporated Derivados de heteroarilo como moduladores de CFTR
UA101493C2 (ru) 2008-03-11 2013-04-10 Инсайт Корпорейшн Производные азетидина и циклобутана как ингибиторы jak
EP2271621B1 (en) * 2008-03-31 2013-11-20 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as cftr modulators
TW200944526A (en) 2008-04-22 2009-11-01 Vitae Pharmaceuticals Inc Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
GB0814340D0 (en) * 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
WO2010080183A1 (en) * 2009-01-08 2010-07-15 The Trustees Of Columbia University In The City Of New York Potent non-urea inhibitors of soluble epoxide hydrolase
US8324250B2 (en) * 2009-03-19 2012-12-04 Hoffmann-La Roche Inc. Piperidine derivatives as NK3 receptor antagonists
WO2010114907A1 (en) 2009-03-31 2010-10-07 Vanderbilt University Sulfonyl-azetidin-3-yl-methylamine amide analogs as glyt1 inhibitors, methods for making same, and use of same in treating psychiatric disorders
WO2010130638A1 (en) * 2009-05-14 2010-11-18 Evotec Ag Sulfonamide compounds, pharmaceutical compositions and uses thereof
AR076920A1 (es) 2009-05-22 2011-07-20 Incyte Corp 3-(4-(7h-pirrolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)octano-o heptano--nitrilo como inhibidores de jak
WO2010135650A1 (en) 2009-05-22 2010-11-25 Incyte Corporation N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
AR078012A1 (es) * 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
WO2011044481A1 (en) 2009-10-09 2011-04-14 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CN102844317B (zh) * 2010-02-18 2015-06-03 因西特公司 作为Janus激酶抑制剂的环丁烷和甲基环丁烷衍生物
PT3050882T (pt) * 2010-03-10 2018-04-16 Incyte Holdings Corp Derivados de piperidin-4-ilazetidina como inibidores de jak1
NZ602838A (en) 2010-04-07 2015-06-26 Vertex Pharma Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof
EP2574168B9 (en) 2010-05-21 2016-10-05 Incyte Holdings Corporation Topical formulation for a jak inhibitor
EP2611778B1 (en) * 2010-09-03 2015-08-05 Forma TM, LLC. Guanidine compounds and compositions for the inhibition of nampt
CA2818545C (en) 2010-11-19 2019-04-16 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
AU2011329734B2 (en) 2010-11-19 2015-05-28 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
PT2675451E (pt) 2011-02-18 2015-10-16 Incyte Corp Terapia de combinação com inibidores mtor/jak
ES2761311T3 (es) 2011-04-01 2020-05-19 Astrazeneca Ab Tratamiento terapéutico
JP2014159375A (ja) * 2011-06-15 2014-09-04 Takeda Chem Ind Ltd アゼパン化合物
ES2560611T3 (es) 2011-06-20 2016-02-22 Incyte Holdings Corporation Derivados de fenil de azetidinilo, carboxamida de piridilo o pirazinilo como inhibidores de JAK
CA2844507A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag Jak pi3k/mtor combination therapy
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
MY175800A (en) 2011-11-30 2020-07-09 Astrazeneca Ab Combination treatment of cancer
US9073960B2 (en) 2011-12-22 2015-07-07 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2013112751A1 (en) * 2012-01-25 2013-08-01 The Trustees Of Columbia University In The City Of New York Potent non-urea inhibitors of soluble epoxide hydrolase
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP2836482B1 (en) 2012-04-10 2019-12-25 The Regents of The University of California Compositions and methods for treating cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
CN104302623A (zh) * 2012-05-01 2015-01-21 住友化学株式会社 哌啶化合物及其有害生物防除用途
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
TWI598325B (zh) * 2012-10-12 2017-09-11 Ｈ 朗德貝克公司 苯甲醯胺類
TW201427947A (zh) 2012-10-12 2014-07-16 Lundbeck & Co As H 環狀胺
BR112015010663B1 (pt) 2012-11-15 2022-12-06 Incyte Holdings Corporation Formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
WO2014085210A1 (en) * 2012-11-29 2014-06-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2934533B1 (en) 2012-12-19 2017-11-15 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9604998B2 (en) 2013-02-18 2017-03-28 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
UA121532C2 (uk) 2013-03-06 2020-06-10 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки при отриманні інгібітора jak
EP2968288B1 (en) 2013-03-15 2018-07-04 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9751881B2 (en) 2013-07-31 2017-09-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP3721873A1 (en) 2013-08-07 2020-10-14 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
US9951052B2 (en) 2013-10-31 2018-04-24 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
MX2016006118A (es) 2013-11-12 2016-07-21 Vertex Pharma Proceso para preparar composiciones farmaceuticas para el tratamiento de enfermedades mediadas por regulador de la conductancia transmembrana de la fibrosis quistica (cftr).
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US10302602B2 (en) 2014-11-18 2019-05-28 Vertex Pharmaceuticals Incorporated Process of conducting high throughput testing high performance liquid chromatography
GB201601301D0 (en) * 2016-01-25 2016-03-09 Takeda Pharmaceutical Novel compounds
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
WO2018135659A1 (ja) * 2017-01-23 2018-07-26 日本ケミファ株式会社 電位依存性ｔ型カルシウムチャネル阻害剤
US11059809B2 (en) 2017-06-20 2021-07-13 Mission Therapeutics Limited Substituted cyanopyrrolidines with activity as DUB inhibitors
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
EA202091830A1 (ru) 2018-01-30 2020-12-29 Инсайт Корпорейшн Способы и промежуточные соединения для получения ингибитора jak
MA52219A (fr) 2018-03-30 2021-02-17 Incyte Corp Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
TW202016090A (zh) * 2018-06-07 2020-05-01 瑞士商愛杜西亞製藥有限公司 經烷氧基取代之吡啶基衍生物
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
AR119162A1 (es) 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo
PE20230251A1 (es) 2019-11-22 2023-02-07 Incyte Corp Terapia de combinacion que comprende un inhibidor de alk2 y un inhibidor de jak2
US12030903B2 (en) 2020-02-18 2024-07-09 Gilead Sciences, Inc. Antiviral compounds
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
WO2023203185A1 (en) * 2022-04-22 2023-10-26 Univerza V Ljubljani Mitochondriotropic benzamide potassium channel k v1.3 inhibitors

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278541A (en) * 1966-10-11 Di-substituted-n-alkyl piperidines
NL130088C (es) * 1960-03-14
DK162087D0 (da) * 1987-03-31 1987-03-31 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
JPH01131172A (ja) 1987-08-28 1989-05-24 Toyama Chem Co Ltd アミン誘導体およびその塩、それらの製造法、並びにそれらを含有する抗潰瘍剤
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
FR2729954B1 (fr) * 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
US5670504A (en) 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
DE69533991T2 (de) * 1995-05-29 2006-04-13 Pfizer Inc. Dipeptide, die die ausschüttung von wachstumshormonen stimulieren
US5631282A (en) * 1995-06-07 1997-05-20 Merck & Co., Inc. Triterpenes
FR2738245B1 (fr) * 1995-08-28 1997-11-21 Sanofi Sa Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
US5696156A (en) 1995-10-31 1997-12-09 Merck & Co. Inc. Triterpene derivatives with immunosuppressant activity
US5679705A (en) 1995-10-31 1997-10-21 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
US5880128A (en) * 1996-05-08 1999-03-09 Schering Corporation Carbonyl piperazinyl and piperidinyl compounds
US6245773B1 (en) * 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
DE19705133A1 (de) 1997-02-11 1998-08-13 Hoechst Ag Sulfonamid-substituierte Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19706675A1 (de) 1997-02-20 1998-08-27 Hoechst Ag Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19707656A1 (de) 1997-02-26 1998-08-27 Hoechst Ag Sulfonamid-substituierte anellierte 7-Ring-Verbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
US6159990A (en) * 1997-06-18 2000-12-12 Synaptic Pharmaceutical Corporation Oxazolidinones as α1A receptor antagonists
CN1265674A (zh) * 1997-07-31 2000-09-06 伊兰药品公司 能抑制由vla－4介导的白细胞粘连的4－氨基苯基丙氨酸化合物
AU1415099A (en) * 1997-11-18 1999-06-07 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
AU767456B2 (en) 1998-07-06 2003-11-13 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
US6423519B1 (en) * 1998-07-15 2002-07-23 Gpc Biotech Inc. Compositions and methods for inhibiting fungal growth
US6303637B1 (en) * 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
EP1038872A1 (en) * 1999-02-22 2000-09-27 Pfizer Products Inc. 4-Phenyl-4-heteroarylpiperdine derivatives as opioid receptor ligands
JP2003505435A (ja) * 1999-06-04 2003-02-12 メルク エンド カムパニー インコーポレーテッド メラノコルチン−４受容体ゴニストとしての置換ピペリジン
AU6951500A (en) * 1999-06-07 2000-12-28 Johns Hopkins University, The Cardiac shock electrode system and corresponding implantable defibrillator system
AU9378801A (en) * 2000-08-31 2002-03-13 Hoffmann La Roche Quinazoline derivatives as alpha-1 adrenergic antagonists
ATE310724T1 (de) * 2000-09-19 2005-12-15 Taiho Pharmaceutical Co Ltd Zusammensetzungen und verfahren zur verwendung achirale analoge von cc1065 und den duocarmycinen
CA2438272A1 (en) * 2001-03-02 2002-10-10 John Macor Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
CA2439691A1 (en) * 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
ES2193839B1 (es) * 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
UA76224C2 (en) * 2001-10-15 2006-07-17 Janssen Pharmaceutica Nv Substituted 4-phenyl 4-[1h-imidazol-2-yl]-piperidine derivatives and use thereof as selective non-peptide delta-opioid agonists
BR0213325A (pt) * 2001-10-15 2004-10-13 Janssen Pharmaceutica Nv Derivados de 4-fenil-4-[1h-imidazol-2-il]-piperidina substituìda para a redução de dano isquêmico
DK1467995T3 (da) * 2001-12-20 2010-09-20 Osi Pharm Inc Pyrrolopyrimidin-A2b-selektive antagonistforbindelser, deres syntese og anvendelse
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
US7435824B2 (en) * 2002-04-19 2008-10-14 Bristol-Myers Squibb Company Prodrugs of potassium channel inhibitors

Also Published As

Publication number Publication date
JP5209670B2 (ja) 2013-06-12
US20040110793A1 (en) 2004-06-10
JP2005529114A (ja) 2005-09-29
WO2003088908A3 (en) 2004-05-27
WO2003088908A2 (en) 2003-10-30
US7582654B2 (en) 2009-09-01
US7005436B2 (en) 2006-02-28
EP2228065A3 (en) 2010-12-22
EP1501467B1 (en) 2012-05-09
PE20040685A1 (es) 2004-10-08
ATE557005T1 (de) 2012-05-15
EP2228065A2 (en) 2010-09-15
US20090312307A1 (en) 2009-12-17
EP2228065B1 (en) 2012-12-26
PL373313A1 (en) 2005-08-22
TW200403058A (en) 2004-03-01
IS7502A (is) 2004-10-12
JP2010215666A (ja) 2010-09-30
EP2371366A1 (en) 2011-10-05
AU2003223651A8 (en) 2003-11-03
ES2388034T3 (es) 2012-10-05
EP1501467A4 (en) 2009-08-19
US20060014792A1 (en) 2006-01-19
AU2003223651A1 (en) 2003-11-03
NO20044351L (no) 2004-10-13
EP1501467A2 (en) 2005-02-02
JP4729259B2 (ja) 2011-07-20

Similar Documents

Publication Publication Date Title
AR040407A1 (es) Compuestos heterociclicos inhibidores de la funcion del canal de potasio
AR038466A1 (es) Inhibidores de cicloalquilo de la funcion del canal de potasio
RS49776B (sr) Fungicidni trifluormetilalkilamino- triazolpirimidini
ES2154990B1 (es) Nuevos colorantes de quinolinio y boratos en composiciones fotopolimerizables.
KR910007525A (ko) 양모제
HUP0002869A2 (hu) Benzotiofén-karboxamid-származékok, ezeket tartalmazó gyógyszerkészítmények, valamint intermedierek
ES2155995T3 (es) Compuestos de 4-fenilpiperidina.
CO5050332A1 (es) Composiciones fungicidas que comprenden 2-metoxibenzofenonas
ES2195433T3 (es) Derivados de adamantano.
FI813283L (fi) Karboxialkyldipeptider foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska kompositioner
ES2171189T3 (es) Derivados de fenilo tri-sustituidos utiles como inhibidores de pde iv.
DE69717268D1 (de) M-amidinophenyl-analoga als faktor-xa-inhibitoren
ES2188957T3 (es) N-(4-(heteroarilmetil)fenil)-heteroarilaminas.
ATE159885T1 (de) Fungizide zusammensetzungen
ATE270271T1 (de) Sulfonamidhydroxamate
CO5040004A1 (es) 2-4-diamino-1,3,5-triazinas, su preparacion y empleo como herbicidas y fitorreguladores
FI853586L (fi) Nya arylaettiksyraderivat.
ES2189183T3 (es) Mezclas fungicidas.
ES2177275T3 (es) Derivados de oxadiazolina y su uso como insecticidas.
MX9205207A (es) Derivados de dihidropiridina, procedimiento para su preparacion y composicion farmaceutica que los comprende
CO5590858A2 (es) Composicion fungicida basada en un derivado de piridilmetilbenzamida e iprovalicarb
CO5580721A2 (es) Composicion fungicida basada en al menos un derivado de piridilmetilbenzamida y al menos un derivado de ditiocarbamato
AR012686A1 (es) Un compuesto de piperazina aril-substituida, composicion farmaceutica que lo contiene y compuestos intermediarios utiles para la preparacion de dicha piperazina
YU47047B (sh) Supstituisani 3-amino-2-benzoilcikloheks-2-enoni, postupak za njihovo dobijanje i primena za dobijanje herbicica
HUP0001009A2 (hu) Herbicid hatású 3-karbamoil/3-tiokarbamoil-szubsztituált 2-benzoil-ciklohexán-1,3-dionok, intermedierjeik, előállításuk és alkalmazásuk

Legal Events

Date Code Title Description
FB Suspension of granting procedure